Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients

Journal of the American College of Cardiology

Volumn 60, Issue 20, 2012, Pages 2032-2040

  Erlinge, David ^a   Ten Berg, Jurrien ^b   Foley, David ^c   Angiolillo, Dominick J ^d   Wagner, Henrik ^a   Brown, Patricia B ^e   Zhou, Chunmei ^e   Luo, Junxiang ^e   Jakubowski, Joseph A ^e   Moser, Brian ^e   Small, David S ^e   Bergmeijer, Thomas ^b   James, Stefan ^f   Winters, Kenneth J ^e  

^a LUND UNIVERSITY   (Sweden)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c Clinical Research Centre   (Ireland)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

coronary artery disease; low body weight; platelet reactivity; prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; CONTUSION; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEMALE; HEMATOMA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN BRUISING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; BODY WEIGHT; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; THIOPHENES; TICLOPIDINE; YOUNG ADULT;

EID: 84868568462     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.08.964     Document Type: Article

References (10)

1. S.D. Wiviott, E. Braunwald, C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
2. R.E. Wrishko, C.S. Ernest, D.S. Small Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 J Clin Pharmacol 49 2009 984 998
3. Prasugrel (Effient) Package Insert 2012 Ely Lilly and Co. Indianapolis, IN
4. Prasugrel (Efient) European Union Summary of Product Characteristics 2012 Ely Lilly and Co. Indianapolis, IN
5. J.S. Riesmeyer, D.E. Salazar, G.J. Weerakkody Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy J Clin Pharmacol 52 2012 789 797
6. C.S. Ernest, D.S. Small, S. Rohatagi Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease J Pharmacokinet Pharmacodyn 35 2008 593 618
7. C.D. Payne, Y.G. Li, D.S. Small Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel J Cardiovasc Pharmacol 50 2007 555 562
8. C.T. Chin, M.T. Roe, K.A. Fox Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial Am Heart J 160 2010 16 22
9. T. Behr, B. Kuch, W. Behr, S.W. von Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI Clin Res Cardiol 100 2011 907 914
10. K.P. Bliden, J. DiChiara, L. Lawal The association of cigarette smoking with enhanced platelet inhibition by clopidogrel J Am Coll Cardiol 52 2008 531 533